VRDN - NASDAQ
Viridian Therapeutics, Inc.
$16.35
+3.0%Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.
At a Glance
Live SnapshotViridian Therapeutics, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Viridian Therapeutics, Inc. Income Statement
VRDN • NASDAQ
| Viridian Therapeutics, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||
70.8M | 302K | 314K | 1.8M | 3M | 1.1M | 4.5M | 8.4M | 4M | 3.3M | 2.5M | 4.3M | 4.3M | 4.4M | |
GROSS PROFIT | ||||||||||||||
(1.2M) | (0.0) | (0.0) | (0.0) | (0.0) | (28.3M) | (32.8M) | (30.4M) | (19.6M) | (2.5M) | (2.5M) | (3.2M) | (2.5M) | (3M) | |
69.7M | 302K | 314K | 1.8M | 3M | -27.3M | -28.3M | -22M | -15.6M | 789K | 66K | 1.1M | 1.8M | 1.4M | |
OPERATING INCOME | ||||||||||||||
(433.1M) | (299.3M) | (254.8M) | (136.1M) | (82.7M) | (83.1M) | (46.4M) | (41.5M) | (30.5M) | (10.5M) | (11.3M) | (8M) | (2.3M) | (4.5M) | |
(95.3M) | (61.1M) | (95M) | (35.2M) | (25.8M) | (13.3M) | (11.6M) | (11M) | (10.9M) | (9.6M) | (10.3M) | (7.8M) | (2.2M) | (4.2M) | |
(338.9M) | (238.3M) | (159.8M) | (100.9M) | (56.9M) | (28.3M) | (34.8M) | (30.4M) | (19.6M) | (888K) | (1M) | (293K) | (96.8K) | (225.4K) | |
-363.4M | -299M | -254.5M | -134.3M | -79.7M | -110.4M | -42M | -33.1M | -26.5M | -12.5M | -11.2M | -6.9M | -196.2K | -4M | |
PRE-TAX INCOME | ||||||||||||||
(4.9M) | (3M) | (1.8M) | (486K) | (3K) | (508K) | (835K) | (873K) | (383K) | (95K) | (141K) | (1M) | (2M) | (1.6M) | |
22.5M | 29.1M | 16.7M | 4.4M | 315K | -335K | 106K | 381K | 20K | -95K | -141K | -1M | -2M | -1.6M | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (41.6M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
20.8M | 29.1M | 16.7M | 4.4M | 315K | -335K | 106K | 381K | 20K | -166K | -141K | -1M | -1.7M | -1.6M | |
-342.6M | -269.9M | -237.7M | -129.9M | -79.4M | -110.7M | -41.9M | -32.7M | -26.5M | -12.7M | -11.3M | -7.9M | -2.2M | -5.6M | |
NET INCOME | ||||||||||||||
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (95K) | (95K) | (0.0) | (0.0) | (2M) | (0.0) | |
-342.6M | -269.9M | -237.7M | -129.9M | -79.4M | -110.7M | -42.4M | -32.7M | -26.5M | -12.7M | -11.3M | -7.9M | -2.2M | -7.2M |
SEC Filings
VRDN - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | June 03, 2026 | June 02, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 28, 2026 | May 27, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 26, 2026 | May 24, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 11, 2026 | May 06, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 05, 2026 | May 05, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 05, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 05, 2026 | May 05, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 17, 2026 | June 02, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 30, 2026 | March 30, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 26, 2026 | December 31, 2025 | 2025 |
Related Guides
Continue your VRDN research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.